Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE)

Tipranks - Tipranks - Sat Nov 15, 2025

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Candel Therapeutics (CADL – Research Report) and Pfizer (PFE – Research Report) with bullish sentiments.

Meet Your ETF AI Analyst

Candel Therapeutics (CADL)

In a report released yesterday, Oliver McCammon from LifeSci Capital maintained a Buy rating on Candel Therapeutics, with a price target of $16.00. The company’s shares closed last Friday at $4.68.

According to TipRanks.com, McCammon is a 5-star analyst with an average return of 131.5% and a 64.0% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Monte Rosa Therapeutics, and Corbus Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Candel Therapeutics with a $18.33 average price target, implying a 304.6% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $25.00 price target.

See the top stocks recommended by analysts >>

Pfizer (PFE)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer yesterday and set a price target of $30.00. The company’s shares closed last Friday at $25.45, close to its 52-week low of $24.48.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 5.4% and a 49.0% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Pfizer with a $29.08 average price target, which is a 13.3% upside from current levels. In a report issued on November 12, Scotiabank also initiated coverage with a Buy rating on the stock with a $30.00 price target.

Read More on CADL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).